Advertisement

Japanese Journal of Radiology

, Volume 33, Issue 10, pp 627–635 | Cite as

Clinical utility of gadoxetate disodium-enhanced hepatic MRI for stereotactic body radiotherapy of hepatocellular carcinoma

  • Yuko NakamuraEmail author
  • Tomoki Kimura
  • Toru Higaki
  • Yukiko Honda
  • Daisuke Komoto
  • Takuji Yamagami
  • Makoto Iida
  • Yasushi Nagata
  • Yohji Honda
  • Hiroshi Aikata
  • Kazuaki Chayama
  • Kazuo Awai
Original Article

Abstract

Purpose

To investigate the utility of gadoxetate disodium-enhanced hepatic MRI (EOB-MRI) for stereotactic body radiotherapy (SBRT) to treat hepatocellular carcinoma (HCC).

Materials and methods

We divided 30 HCC patients who underwent SBRT into group A (no change in their Child-Pugh score 6 months post-SBRT) and group B (increased score 6 months post-SBRT). EOB-MRI was performed before and 6 months after SBRT. We calculated the liver-spleen contrast (LSC) ratio for each radiation dose area on hepatobiliary phase scans (LSCbefore using images obtained before SBRT and LSCafter using images acquired after SBRT) and the weighted LSC (W-LSC) as: [(mean LSCbefore (0–30 Gy) × liver volume (0–30 Gy) + mean LSCbefore (30 Gy-) × liver volume (30 Gy-))/total liver volume]. Then we compared the W-LSC, percentage of the liver volume exposed to >20 Gy (V20), and mean liver dose in the two groups.

Results

The LSCafter at 48, 40, and 30 Gy to the liver was statistically lower than the unirradiated area of the liver (p < 0.01). Univariate analysis showed that only W-LSC was significantly associated with group B (p = 0.02).

Conclusion

W-LSC was a useful parameter for predicting changes in hepatic function after SBRT.

Keywords

Hepatocellular carcinoma Stereotactic body radiotherapy Gadoxetate disodium Magnetic resonance imaging 

Notes

Compliance with ethical standards

Conflict of interest

Kazuo Awai received a research grant from Toshiba Medical Systems Co., Ltd. The other authors declare that they have no conflict of interest.

Ethical statement

None.

References

  1. 1.
    Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute clinical trials planning meeting. J Clin Oncol. 2010;28(25):3994–4005.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 2003;52(Suppl 3):1–8.Google Scholar
  3. 3.
    Ikai I, Kudo M, Arii S, Omata M, Kojiro M, Sakamoto M, et al. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res. 2010;40:1043–59.CrossRefGoogle Scholar
  4. 4.
    Takeda A, Takahashi M, Kunieda E, Takeda T, Sanuki N, Koike Y, et al. Hypofractionated stereotactic radiotherapy with and without transarterial chemoembolization for small hepatocellular carcinoma not eligible for other ablation therapies: preliminary results for efficacy and toxicity. Hepatol Res. 2008;38(1):60–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Takeda A, Sanuki N, Eriguchi T, Kobayashi T, Iwabutchi S, Matsunaga K, et al. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29(2):372–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S94–100.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Takeda A, Oku Y, Sanuki N, Kunieda E, Koike N, Aoki Y, et al. Dose volume histogram analysis of focal liver reaction in follow-up multiphasic CT following stereotactic body radiotherapy for small hepatocellular carcinoma. Radiother Oncol. 2012;104(3):374–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Dawson LA, Ten Haken RK, Lawrence TS. Partial irradiation of the liver. Semin Radiat Oncol. 2001;11(3):240–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Liang SX, Zhu XD, Xu ZY, Zhu J, Zhao JD, Lu HJ, et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys. 2006;65(2):426–34.CrossRefPubMedGoogle Scholar
  10. 10.
    Huppertz A, Balzer T, Blakeborough A, Breuer J, Giovagnoni A, Heinz-Peer G, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology. 2004;230(1):266–75.CrossRefPubMedGoogle Scholar
  11. 11.
    Ichikawa T, Saito K, Yoshioka N, Tanimoto A, Gokan T, Takehara Y, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol. 2010;45(3):133–41.CrossRefPubMedGoogle Scholar
  12. 12.
    Di Martino M, Marin D, Guerrisi A, Baski M, Galati F, Rossi M, et al. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis. Radiology. 2010;256(3):806–16.CrossRefPubMedGoogle Scholar
  13. 13.
    Bluemke DA, Sahani D, Amendola M, Balzer T, Breuer J, Brown JJ, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: US multicenter phase III study. Radiology. 2005;237(1):89–98.CrossRefPubMedGoogle Scholar
  14. 14.
    Motosugi U, Ichikawa T, Sou H, Sano K, Tominaga L, Kitamura T, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging. 2009;30(5):1042–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Morita K, Namimoto T, Awai K, Komi M, Hashida M, Tsuji T, et al. Enhancement effects of hepatic dynamic MR imaging at 3.0 T and 1.5 T using gadoxetic acid in a phantom study: comparison with gadopentetate dimeglumine. Magn Reson Med. 2011;66(1):213–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Rueckert D, Sonoda LI, Hayes C, Hill DL, Leach MO, Hawkes DJ. Nonrigid registration using free-form deformations: application to breast MR images. IEEE Trans Med Imaging. 1999;18(8):712–21.CrossRefPubMedGoogle Scholar
  17. 17.
    Shinagawa Y, Sakamoto K, Fujimitsu R, Shimakura M, Kora S, Takano K, et al. Pseudolesion of the liver on gadoxetate disodium-enhanced MR images obtained after transarterial chemoembolization for hepatocellular carcinoma: clinicoradiologic correlation. Am J Roentgenol. 2012;199(5):1010–7.CrossRefGoogle Scholar
  18. 18.
    Sanuki N, Takeda A, Oku Y, Eriguchi T, Nishimura S, Aoki Y, et al. Threshold doses for focal liver reaction after stereotactic ablative body radiation therapy for small hepatocellular carcinoma depend on liver function: evaluation on magnetic resonance imaging with Gd-EOB-DTPA. Int J Radiat Oncol Biol Phys. 2014;88(2):306–11.CrossRefPubMedGoogle Scholar
  19. 19.
    Kimura T, Takahashi S, Kenjo M, Nishibuchi I, Takahashi I, Takeuchi Y, et al. Dynamic computed tomography appearance of tumor response after stereotactic body radiation therapy for hepatocellular carcinoma: how should we evaluate treatment effects? Hepatol Res. 2013;43(7):717–27.CrossRefPubMedGoogle Scholar
  20. 20.
    Sanuki N, Takeda A, Mizuno T, Oku Y, Eriguchi T, Iwabuchi S, et al. Tumor response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis. Am J Roentgenol. 2013;201(6):W812–20.CrossRefGoogle Scholar
  21. 21.
    Takeda A, Oku Y, Sanuki N, Kunieda E, Koike N, Aoki Y, et al. Dose volume histogram analysis of focal liver reaction in follow-up multiphasic CT following stereotactic body radiotherapy for small hepatocellular carcinoma. Radiother Oncol. 2012;104(3):374–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Sanuki-Fujimoto N, Takeda A, Ohashi T, Kunieda E, Iwabuchi S, Takatsuka K, et al. CT evaluations of focal liver reactions following stereotactic body radiotherapy for small hepatocellular carcinoma with cirrhosis: relationship between imaging appearance and baseline liver function. Br J Radiol. 2010;83(996):1063–71.PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Okamoto D, Nishie A, Asayama Y, Tajima T, Ishigami K, Kakihara D, et al. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MR finding of radiation-induced hepatic injury: relationship to absorbed dose and time course after irradiation. Magn Reson Imaging. 2014;32(6):660–4.CrossRefPubMedGoogle Scholar
  24. 24.
    Kim SH, Lee J, Kim MJ, Jeon YH, Park Y, Choi D, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. Am J Roentgenol. 2009;192(6):1675–81.CrossRefGoogle Scholar
  25. 25.
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Matsumata T, Kanematsu T, Yoshida Y, Furuta T, Yanaga K, Sugimachi K. The indocyanine green test enables prediction of postoperative complications after hepatic resection. World J Surg. 1987;11(5):678–81.CrossRefPubMedGoogle Scholar
  27. 27.
    Lau H, Man K, Fan ST, Yu WC, Lo CM, Wong J. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg. 1997;84(9):1255–9.CrossRefPubMedGoogle Scholar

Copyright information

© Japan Radiological Society 2015

Authors and Affiliations

  • Yuko Nakamura
    • 1
    Email author
  • Tomoki Kimura
    • 2
  • Toru Higaki
    • 1
  • Yukiko Honda
    • 1
  • Daisuke Komoto
    • 1
  • Takuji Yamagami
    • 1
    • 5
  • Makoto Iida
    • 1
  • Yasushi Nagata
    • 2
  • Yohji Honda
    • 3
    • 4
  • Hiroshi Aikata
    • 3
    • 4
  • Kazuaki Chayama
    • 3
    • 4
  • Kazuo Awai
    • 1
  1. 1.Diagnostic RadiologyHiroshima UniversityHiroshimaJapan
  2. 2.Radiation OncologyHiroshima UniversityHiroshimaJapan
  3. 3.Departments of Medicine and Molecular ScienceHiroshima UniversityHiroshimaJapan
  4. 4.Hiroshima Liver Research Project CenterHiroshimaJapan
  5. 5.Department of RadiologyKochi UniversityNankokuJapan

Personalised recommendations